IFPMA Statement @WHA 71 agenda item 11.7 Preparation for the third High-level Meeting of the General Assembly on the Prevention and Control of Non-communicable Diseases, to be held in 2018
Delivered by Mareike Ostertag, IFPMA
The innovative pharmaceutical industry, represented by IFPMA echoes WHO concerns that progress achieved on prevention and control of NCDs has been patchy and insufficient. We share the concern that SDG 3.4 will not be met if efforts are not significantly increased at all levels.
We also agree that integrated strategies that include prevention, treatment and care as are crucial. Investments in better management of NCDs is also an essential component of any national response to this challenge.
Meaningful progress and sustainable solutions can only be found in a multi-sectorial approach and we call for recognition of the value that the healthcare and pharmaceutical industry brings.
We have been playing a significant role in addressing NCDs for many years through a large number of access programs and collaborations with the public sector. As an industry, we are committed to continue to work with all stakeholders towards achieving SDG 3.4 and 17 by engaging in partnerships to contribute to WHO and Member States’ Health objectives, including to achieve UHC.
With Access Accelerated, 24 innovation-based biopharmaceutical companies have raised collaboration to an unprecedented level by partnering with countries, civil society, other non-pharmaceutical companies, academia, the WB and NGOs to drive cross-sectorial dialogue, support capacity building and to drive implementation of action plans.
IFPMA supports the need to ensure that a consensus is reached on the extent to which the obstacles identified in the report impede progress towards SDG 3.4. We also want to emphasise that implementation of the WHO best buys and strategies for financing NCDs remain two essential areas where significant improvements and results from Member States and the international community are still required.
Given the lack of sufficient progress and the scale of the global health problem that NCDs poses, there is an urgent need to work together and decisively on NCDs. As a committed stakeholder in the fight against NCDs, we would be keen to develop bold and concrete collaborations with WHO on prevention and control of NCDs.
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. The industry’s two million employees discover, develop, and deliver medicines and vaccines that advance global health.Learn more
Media ContactAbigail Jones email@example.com